The Australian Advantage, combined with the iNGENū advantage will reward sponsors with highly cost-effective, high quality, favourable conditions and valuable data.

Sponsors will truly value the rapid start-up, leveraging 43.5% Government R&D rebates to reduce costs, and delivering internationally accepted quality data from world-leading clinical settings, KOLs and PIs.

No IND required

Our cannabinoid & psychedelic research clients start their Phase I without having to wait for an IND from the FDA, saving up to a year in regulatory timelines and considerable costs.

Rapid IRB/EC approval

Our clients are currently experiencing a 3- 5 week IRB/EC turnaround due to the supportive regulatory and clinical environment, and iNGENū’s experience.

World-class data

Australian GCP Clinical data is accepted by all the major regulatory authorities including the FDA and EMA.

Proven site network across Australia and New Zealand

iNGENū CRO has a powerful Australian and New Zealand network of proven PIs and clinical sites.

5-6 week start-up

With the Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks it enables you to get access to clinical data quickly and gain that critical Go/No Go information on your product faster than anywhere else in the world.